Pregled bibliografske jedinice broj: 1050352
Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients’ Pharmacogenetic Profile
Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients’ Pharmacogenetic Profile // Basic & Clinical Pharmacology & Toxicology, 123 (2018), 4; 509-518 doi:10.1111/bcpt.13035 (međunarodna recenzija, prikaz, znanstveni)
CROSBI ID: 1050352 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Rosuvastatin-Induced Rhabdomyolysis - Possible Role
of Ticagrelor and Patients’ Pharmacogenetic Profile
Autori
Vrkić Kirhmajer, Majda ; Macolić Šarinić, Viola ; Šimičević, Livija ; Ladić, Iva ; Putarek, Krešimir ; Banfić, Ljiljana ; Božina, Nada
Izvornik
Basic & Clinical Pharmacology & Toxicology (1742-7835) 123
(2018), 4;
509-518
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, prikaz, znanstveni
Ključne riječi
DRUG-DRUG INTERACTIONS ; PHARMACOKINETIC INTERACTION ; HEALTHY-VOLUNTEERS ; 2017 ESC ; AMIODARONE ; POLYMORPHISMS ; SIMVASTATIN ; METABOLITES ; MANAGEMENT ; ELEVATION
Sažetak
Up to the beginning of 2018, a total of eight cases describing rare but clinically important drug interactions between rosuvastatin and ticagrelor which resulted in rhabdomyolysis have been noted in the Global World Health Organization (WHO) adverse drug reaction (ADR) database (VigiBase) as well as in available literature. There are several possible factors which could contribute to the onset of rhabdomyolysis: old age, initially excessive rosuvastatin dose, drug- drug interactions (DDI) on metabolic enzymes (CYPs and UGTs) and drug transporter levels (ABCB1, ABCG2, OATP1B1) and pharmacogenetic predisposition. We reviewed all available cases plus the case of an 87-year-old female Croatian/Caucasian patient who developed rhabdomyolysis following concomitant treatment with rosuvastatin and ticagrelor. The results of the pharmacogenetic analysis indicated that the patient was a carrier of inactivating alleles CYP2C9*1/*3, CYP3A4*1/*22, CYP3A5*3/*3, CYP2D6*1/*4, UGT1A1*28/*28, UGT2B7 -161C/T, ABCB1 3435C/T and ABCB1 1237C/T which could have added to the interactions not only between ticagrelor and rosuvastatin but also other concomitantly prescribed medicines, such as amiodarone and proton pump inhibitors. In this case report, the possible multifactorial causes for rhabdomyolysis following concomitant use of rosuvastatin and ticagrelor such as old age, polypharmacy, renal impairment, along with pharmacogenetics will be discussed
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb
Profili:
Krešimir Putarek
(autor)
Viola Macolić-Šarinić
(autor)
Nada Božina
(autor)
Majda Vrkić Kirhmajer
(autor)
Ljiljana Banfić
(autor)
LIVIJA ŠIMIČEVIĆ
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE